Lymphoma, Non-Hodgkin's Clinical Trial
Official title:
A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00363636 -
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
|
Phase 3 | |
| Terminated |
NCT00594308 -
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
N/A | |
| Terminated |
NCT02518750 -
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
|
Phase 2 | |
| Completed |
NCT01733238 -
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Terminated |
NCT00384150 -
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
|
Phase 3 | |
| Terminated |
NCT00141700 -
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Terminated |
NCT00143884 -
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
|
Phase 2 | |
| Completed |
NCT02750670 -
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 2 | |
| Terminated |
NCT02473523 -
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia
|
N/A | |
| Completed |
NCT00161590 -
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
|
Phase 1 | |
| Terminated |
NCT00651443 -
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04756726 -
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
|
Phase 1/Phase 2 | |
| Terminated |
NCT00395967 -
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
|
Phase 2 | |
| Completed |
NCT00143871 -
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
|
Phase 2 |